Participated · Equity · Jul 2026

TytoCare develops a clinician-grade handheld remote examination platform paired with FDA-cleared AI-powered software-as-a-medical-device algorithms to enable comprehensive remote physical exams. The company serves health systems, payers, and employer health programs and is positioning its platform for cardiopulmonary screening, oncology supportive care, and chronic disease management including CHF and COPD. TytoCare announced leadership appointments of Adam Pellegrini as CEO and Greg Orr as COO concurrent with its $25M+ growth round led by Insight Partners. The company intends to use the new capital to expand its AI algorithm pipeline, deepen integrations with health systems and payers, and accelerate go-to-market efforts. TytoCare is headquartered in New York and Netanya, Israel, and emphasizes FDA-cleared diagnostic fidelity as a competitive differentiator.

Participated · Series C · Jun 2026

InStride Health delivers virtual specialty outpatient care for pediatric anxiety and obsessive-compulsive disorder using cognitive behavioral therapy with a focus on exposure therapy. It provides multidisciplinary care teams—typically a therapist, an exposure coach and a psychiatrist—that develop personalized care plans and communicate with patients and families via text, phone or video. The company serves patients ages seven to 24 and currently operates in 17 states, having treated more than 5,000 patients. Reported outcomes include 97% of graduates showing overall clinical improvement and over 99% of patients remaining out of the hospital one year after discharge. Caregiver impacts reported include an 81% reduction in caregiver stress and more than 90% reporting reduced missed work. InStride aims to expand access to evidence-based specialty care while preserving its clinical outcomes as it grows into new and existing markets.

Participated · Series A · May 2026

Optura provides an enterprise platform that maps fragmented organizational data into a unified knowledge layer, scores and ranks AI use cases, simulates projected returns, and deploys and monitors AI agents across healthcare organizations. The ROAI™ discipline emphasizes measuring and tracking live performance against projected value to move organizations from experimentation to measurable outcomes. Optura reports more than $2 billion in AI initiatives on its platform, $120 million in tracked value, 700% ROAI™ on in-flight initiatives, and over 250 identified use cases. The company plans to invest the Series A proceeds in expanding AI capabilities, enlarging platform teams and scaling partnerships with large language model providers. Optura has commercial customers that include enterprise health plans and providers such as Independence Blue Cross, Prime Therapeutics and Ardent Health.

Led · Equity · Mar 2026

Lantern partners with employers and health plans to expand its presence in employer-sponsored and plan-sponsored healthcare channels. The company announced a $30 million raise aimed at accelerating growth with employers and health plans. The round was led by Morgan Health and Echo Health Ventures, signaling strategic backing from employer-healthcare and health-plan-aligned investors. The coverage does not disclose revenue, user metrics, or prior funding details. Lantern plans to use the new capital to drive expansion within employer and health-plan markets.

Participated · Series C · Feb 2026

Codoxo offers a Generative AI-powered Unified Cost Containment Platform that spans the entire claim lifecycle, with its flagship Point Zero Payment Integrity model intervening before claims are even submitted. By combining proactive provider education, data mining, clinical chart review, deepfake detection, and policy-to-code automation, the platform reduces downstream denials and overpayments while strengthening payer–provider relationships. The company supports payment integrity operations across more than 80 million covered lives and reports 100 % customer retention and 125 % net revenue retention for 2025. Customer implementations have delivered $12–$16 PMPY in savings at the pre-claim stage and up to $66 PMPY across the broader payment spectrum. Codoxo has earned recognition from Inc. 5000, Everest Group, Black Book Research, and the A.I. Awards, underscoring its category leadership. Recent product launches include the Data Health Integrity Agent and generative-AI-driven Policy-to-Code capabilities. With continued compliance achievements such as NIST 800-53 Rev 5 and HITRUST r2 certification, Codoxo is positioning itself for accelerated national expansion.